"The U.S. Court of Appeals for the Federal Circuit (CAFC) on Monday issued a decision that affirmed in part, vacated in part, and remanded a ruling from the U.S. District Court for the District of Massachusetts in a patent dispute between Maquet Cardiovascular LLC and Abiomed Inc. The Federal Circuit agreed with the lower court that certain claims of one Maquet patent were not infringed by Abiomed's Impella heart pumps, but revived Maquet's infringement allegations on five other patents after finding the district court had improperly construed key claim terms."
"Abiomed originally filed the lawsuit in May 2016, seeking a court declaration that its Impella devices did not infringe six of Maquet's patents and that the patents were invalid. The patents at issue, U.S. Patent Nos. 7,022,100, 8,888,728, 9,327,068, 9,545,468, 9,561,314, and 9,597,437 are directed to intravascular blood pump systems and methods for providing heart support. The technology involves placing a small pump within a patient's circulatory system to assist the heart."
The Federal Circuit affirmed in part, vacated in part, and remanded a decision from the District of Massachusetts in a patent dispute between Maquet and Abiomed. The court held that certain claims of Maquet's '100 patent were not infringed by Abiomed's Impella heart pumps. The court concluded that the district court had improperly construed key claim terms and revived Maquet's infringement allegations as to five other patents. Abiomed had sought declaratory judgments in May 2016, asserting noninfringement and invalidity of six Maquet patents directed to intravascular blood pump systems. The district court conducted a Markman hearing in 2018, later granting summary judgment of noninfringement and entering final judgment in 2023, prompting Maquet's appeal.
Read at IPWatchdog.com | Patents & Intellectual Property Law
Unable to calculate read time
Collection
[
|
...
]